NAPROSYN (naproxen) by Hamilton medical is cyclooxygenase inhibitors [moa]. First approved in 1976.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
NAPROSYN (naproxen) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce pain, inflammation, and fever. Approved in 1976, it is indicated for various pain and inflammatory conditions including arthritis, menstrual cramps, and acute pain. The drug works by blocking prostaglandin synthesis, providing both analgesic and anti-inflammatory effects.
With LOE approaching and moderate competitive pressure, the NAPROSYN team likely focuses on generic defense strategies and managed care retention rather than growth initiatives.
Cyclooxygenase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain
A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain
Worked on NAPROSYN at Hamilton medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NAPROSYN offers career opportunities primarily in commercial and market access functions focused on protecting share against generics and managing payer relationships. This is a maintenance and defense role rather than a growth or innovation platform, suited for professionals skilled in competitive markets and stakeholder management.